News

Video

Camrelizumab Plus Rivoceranib vs Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): Final Overall Survival Analysis of the Phase 3 CARES-310 Study

Author(s):

This is a final overall survival analysis on the phase 3 CARES-310 study (NCT03764293), a randomized, open-label, international phase 3 trial comparing camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC).

Related Videos
Ciara Kelly, MBBCh, BAO
Mark Agulnik, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Jonathan C. Trent, MD, PhD
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
utinib vs. Acalabrutinib in B-Cell Malignancies: An Adverse Event-Based Economic Analysis
Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma